Date:10/20/2011

ingent consideration expense, (c) a gain on an acquisition-related milestone receipt, (d) due diligence, other fees and exit costs, and (e) an inventory step-up adjustment. The acquisition-related gains on previously held equity interests is a non-recurring benefit associated with acquisitions completed in the first quarter of 2011. Contingent consideration expense is a non-cash charge representing accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. The gain on an acquisition-related milestone resulted from a 2010 receipt related to Guidant Corporation's sale of its vascular intervention and endovascular solutions businesses to Abbott Laboratories, and is not indicative of future operating results.  Due diligence, other fees and exit costs include legal, tax, severance and other expenses associated with prior acquisitions that are not representative of on-going operations. The inventory step-up adjustment is a non-cash charge related to acquired inventory directly attributable to prior acquisitions and is not indicative of the Company's on-going operations, or on-going cost of products sold. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

Divestiture-related (credits) charges - These amounts represent (a) gains resulting from business divestitures and (b) fees and separation costs associated with business divestitures. The Company completed the sale of its Neurovascular business in January 2011 and the resulting gain is not indicative of future operating performance and is not used by management to assess operating performance. Fees and separation costs represent those associated w
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
2. Boston Scientific Launches Promus Element™ Stent System In China
3. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
4. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
5. COPAN WASP® Lands at Prestigious Boston Medical Center
6. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
8. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
9. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
10. Boston Scientific Launches Coyote™ Balloon Catheter
11. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders